Cannabis Law Report

JUNE 7, 2022

On the contrary, researchers are leaning more towards CBD as a beneficial chemical with therapeutic effects on various physical and mental health problems, from anxiety to chronic pain. Relieves Chronic Pain. Other studies found encouraging results on neuropathic pain, arthritis pain, and multiple sclerosis.

Chronic Pain 52

Chronic Pain CBD Digestion Edibles 52

Cannabis Law Report

AUGUST 26, 2019

Chronic pain. One area that reports looked closely was, use of medical marijuana to treat chronic pain. Chronic pain is a foremost cause of disability that affects more than 25 million adults in the U.S. Chronic pain is a foremost cause of disability that affects more than 25 million adults in the U.S.

Chronic Pain 45

Chronic Pain Clinical Trials Epilepsy Conditions 45

Cannabis Law Report

SEPTEMBER 6, 2021

The steadily aging population across the globe has played a significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 24, 2021

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to treat aging and longevity, autoimmune diseases, and COVID-19- associated depression and cytokine elevation.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Canna Care Docs

DECEMBER 16, 2020

Chronic pain. One of the most widespread uses of medical marijuana is for chronic pain. Next to chronic pain, treatment for multiple sclerosis is the second most common reason people seek medical marijuana in the US. Multiple sclerosis.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

NOVEMBER 24, 2019

Chronic pain. Severe treatment-resistant epilepsy. Chronic pain. Do not offer the following to manage chronic pain in adults: nabilone. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. This study is, of course, well-vetted, and has offered plenty of hope to sufferers of epilepsy. According to various clinical trials, individuals who took CBD before speaking publicly in front of a big audience were able to remain calm and deliver their remarks with relative ease. Chronic Pain.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., This is because Epidiolex has been proven an effective treatment after going through various clinical trials. after its consumption.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Leafwell

MARCH 11, 2019

How it works and what effect it has on the body is not precisely known, partially because far more clinical trials need to take place before we can say anything for sure, and partially because research on cannabinoids – even the non-psychoactive/non-intoxicating ones – is still restricted in many parts of the world.

Clinical Trials 68

Clinical Trials CBD Cannabinoids Chronic Pain 68

MMJ Recs

DECEMBER 22, 2023

Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. One significant factor is the recognition of the opioid crisis and the need for alternative pain management strategies.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Dr. Chapman Bio. Chapman has operated Chapman Pharmaceutical Consulting, Inc.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

JANUARY 1, 2020

Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer. With increasing social acceptance more doctors feel comfortable recommending it to treat chronic pain. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Acceptance of Medicinal Cannabis.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

CannaTech

SEPTEMBER 16, 2018

But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression. This knowledge gap isn’t surprising, as cannabis as a medicine is non-traditional in its very nature.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Puff Puff Post

JANUARY 1, 2020

Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer. With increasing social acceptance more doctors feel comfortable recommending it to treat chronic pain. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Acceptance of Medicinal Cannabis.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

JANUARY 5, 2022

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Miss Marijuana

MARCH 15, 2021

Many people tout this strain’s powerful effect on their lives, and it will be curious to see what the medical community does once clinical trials are initiated. Chronic stress. Chronic Pain. Ringo’s Gift may help with the following conditions: Anxiety. Depression. Muscle Spasms. Inflammation.

Strains 52

Strains Indica Sativa Hybrid 52

Cannabis Law Report

JANUARY 24, 2022

The CBD segment dominated the market in 2021 due to the growing awareness about the positive effects of CBD for the treatment of various medical conditions, such as chronic pain, cancer & multiple sclerosis. Growing adoption of medical marijuana for treatment of chronic diseases. Chronic Pain. Market Dynamics.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

The Joint Blog

APRIL 22, 2022

Treats Epilepsy. Furthermore, the FDA recognizes the benefits of CBD oil and has approved many branded oils to treat some forms of epilepsy. The opioid crisis is a major issue that many Americans suffer from, but many preclinical trials and human clinical trials suggest that CBD might help people reduce their dependence on opioids.

Oil 26

Oil CBD Topical Clinical Trials 26

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness. Epilepsy & behavior case reports 9 (2018): 10. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

JULY 15, 2019

ACM takes in consideration the characteristics of medical cannabis preparations and substances, and is a simplified version of the marketing authorization required for medicinal products to some extent (for instance, no clinical trials are required).

Medicine 40

Medicine Clinical Trials Patients Access 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. For example, most statin drugs can cause memory issues, muscle pain, fatigue and muscle weakness. Epilepsy & behavior case reports 9 (2018): 10. [4]

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., For more information, please visit www.virpaxpharma.com. About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Leafwell

MARCH 11, 2020

How it works and what effect it has on the body is not precisely known, partially because far more clinical trials need to take place before we can say anything for sure. Cannabidiol (CBD) is still a big mystery in many ways. Research even into non-psychoactive/non-intoxicating cannabinoids is restricted in many parts of the world.

Clinical Trials 10

Clinical Trials CBD Cannabinoids Chronic Pain 10

Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 Forward-Looking Statement.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

SEPTEMBER 9, 2021

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Global Legal Cannabis Industry: Number of Clinical Trials, By Region. Chronic Pain.

Recreational 95

Recreational Hemp THC Legalization 95